Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AB 163

Known as: AB-163, bis(2,2-dimethyl-1-aziridinyl)phosphinic acid ethyl ester 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryEthylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163) was used to treat 27 patients in a phase I trial. The limiting… Expand
  • table 1
  • table 2
1985
1985
In continuation of efforts to improve the antitumor selectivity of the 2,2-dimethylaziridine class of alkylating agents, a series… Expand
1982
1982
Ethyl bis (2,2 dimethyl-1-aziridinyl) phosphinate (AB-163), a TEPA analogue, was used with radiation therapy in treating 18… Expand
1979
1979
Abstract Ethyl bis(2,2-dimethyl-i-aziridinyl) phosphinate (AB-163), a new tris(aziridinyl) phosphine oxide (TEPA) analogue, was… Expand
1979
1979
Abstract Three 2,2-dimethyl phosphoraziridines, bis(2,2-dimethylaziridinyl)phosphinyl urethane (AB-132, NSC 51325), ethyl bis(2,2… Expand
1975
1975
Abstract The effects of cyclophosphamide (CTX) and of alkylating agents containing aziridine or 2,2-dimethylaziridine moieties on… Expand
1969
1969
AB‐163, a new alkylating agent containing the 2,2‐dimethylaziridine moiety, was found to be active against a number of… Expand